BRPI0917661A2 - produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan - Google Patents

produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan

Info

Publication number: BRPI0917661A2
Authority: BR; Brazil
Prior art keywords: macitentan; pharmaceutical composition; composition containing; product containing; product
Prior art date: 2008-08-13

Application number

BRPI0917661A

Other languages

English (en)

Inventor

Martine Clozel

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-13

Filing date

2009-08-12

Publication date

2015-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917661(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-08-12 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2015-12-01 Publication of BRPI0917661A2 publication Critical patent/BRPI0917661A2/pt

2019-12-17 Publication of BRPI0917661B1 publication Critical patent/BRPI0917661B1/pt

2021-05-25 Publication of BRPI0917661B8 publication Critical patent/BRPI0917661B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

BRPI0917661A 2008-08-13 2009-08-12 produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina BRPI0917661B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2008053252		2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en)	2008-08-13	2009-08-12	Therapeutic compositions containing macitentan

Publications (3)

Publication Number	Publication Date
BRPI0917661A2 true BRPI0917661A2 (pt)	2015-12-01
BRPI0917661B1 BRPI0917661B1 (pt)	2019-12-17
BRPI0917661B8 BRPI0917661B8 (pt)	2021-05-25

Family

ID=41346591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0917661A BRPI0917661B8 (pt)	2008-08-13	2009-08-12	produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina

Country Status (30)

Country	Link
US (3)	US8809334B2 (pt)
EP (2)	EP2315587B1 (pt)
JP (3)	JP5764061B2 (pt)
KR (1)	KR101678699B1 (pt)
CN (1)	CN102099026B (pt)
AR (1)	AR073031A1 (pt)
AU (1)	AU2009280843B2 (pt)
BR (1)	BRPI0917661B8 (pt)
CA (1)	CA2731370C (pt)
CY (2)	CY1119826T1 (pt)
DK (2)	DK3300729T3 (pt)
ES (2)	ES2652590T3 (pt)
HK (1)	HK1253355B (pt)
HR (2)	HRP20171917T1 (pt)
HU (2)	HUE047767T2 (pt)
IL (1)	IL211143A0 (pt)
LT (2)	LT3300729T (pt)
MA (1)	MA32614B1 (pt)
MX (1)	MX350011B (pt)
MY (1)	MY178894A (pt)
NO (1)	NO2315587T3 (pt)
NZ (1)	NZ591601A (pt)
PL (2)	PL3300729T3 (pt)
PT (2)	PT2315587T (pt)
RU (1)	RU2519161C2 (pt)
SI (2)	SI3300729T1 (pt)
SM (2)	SMT201900740T1 (pt)
TW (1)	TWI446911B (pt)
WO (1)	WO2010018549A2 (pt)
ZA (1)	ZA201101900B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1928409T3 (pl)	2005-09-12	2013-02-28	Actelion Pharmaceuticals Ltd	Trwała kompozycja farmaceutyczna zawierająca pirymidynosulfamid
MX2010001837A (es)	2007-08-17	2010-03-10	Actelion Pharmaceuticals Ltd	Derivados de 4-pirimidinasulfamida.
USRE46364E1 (en) *	2008-02-28	2017-04-11	Nippon Shinyaku Co., Ltd.	Fibrosis inhibitor
HRP20171917T1 (hr)	2008-08-13	2018-02-09	Actelion Pharmaceuticals Ltd.	Terapeutski pripravci koji sadrže macitentan
US9505737B2 (en)	2013-01-11	2016-11-29	Corsair Pharma, Inc.	Treprostinil derivative compounds and methods of using same
WO2014110491A1 (en)	2013-01-11	2014-07-17	Theratrophix Llc	Prodrugs of treprostinil
US9394227B1 (en)	2015-06-17	2016-07-19	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en)	2015-06-17	2017-05-09	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en)	2016-04-29	2017-10-17	Corning Optical Communications Wireless Ltd	Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
MX2019006938A (es)	2016-12-14	2019-09-06	Respira Therapeutics Inc	Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
EP3849560A4 (en) *	2018-09-14	2022-06-08	Pharmosa Biopharm Inc.	PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF WEAK ACID DRUGS AND THEIR USES
LT3897646T (lt) *	2018-12-21	2024-07-10	Actelion Pharmaceuticals Ltd	Macitentanas plaučių arterinei hipertenzijai gydyti
TW202042818A (zh)	2019-01-25	2020-12-01	瑞士商艾克泰聯製藥有限公司	用於治療慢性血栓性肺高血壓之醫藥組成物
BR112022010311A2 (pt)	2019-11-29	2022-08-16	Actelion Pharmaceuticals Ltd	Métodos de tratamento de hipertensão arterial pulmonar
WO2021126884A1 (en)	2019-12-16	2021-06-24	Tenax Therapeutics, Inc.	LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
US20250064799A1 (en)	2021-12-31	2025-02-27	Tenax Therapeutics, Inc.	Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1097239A (en)	1976-05-11	1981-03-10	Salvador Moncada	Enzymatic preparation of prostacyclin and its salts
DE2845770A1 (de)	1978-10-19	1980-04-30	Schering Ag	Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja)	1982-01-20	1983-07-25	Toray Ind Inc	５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en)	1984-03-08	1987-07-28	The Upjohn Company	Interphenylene carbacyclin derivatives
AU2002227984B8 (en) *	2000-12-18	2007-01-04	Actelion Pharmaceuticals Ltd.	Novel sulfamides and their use as endothelin receptor antagonists
HUP0303315A2 (hu) *	2000-12-19	2004-01-28	Merck Patent Gmbh.	Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények
DE10100426B4 (de)	2001-01-08	2006-04-06	Steag Hamatech Ag	Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (pt) *	2001-04-26	2009-10-21	Nippon Shinyaku Co Ltd
WO2004017993A1 (en)	2002-08-12	2004-03-04	Actelion Pharmaceuticals Ltd	Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
MXPA05005793A (es)	2002-12-02	2005-08-16	Actelion Pharmaceuticals Ltd	Pirimidina-sulfamidas y su uso como antagonistas de receptor de endotelina.
US20050101608A1 (en) *	2003-09-24	2005-05-12	Santel Donald J.	Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) *	2004-11-11	2006-08-16	Actelion Pharmaceuticals Ltd	Novel sulfamides
PL1928409T3 (pl)	2005-09-12	2013-02-28	Actelion Pharmaceuticals Ltd	Trwała kompozycja farmaceutyczna zawierająca pirymidynosulfamid
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
HRP20140215T1 (hr)	2008-02-20	2014-04-11	Actelion Pharmaceuticals Ltd.	Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika
HRP20171917T1 (hr)	2008-08-13	2018-02-09	Actelion Pharmaceuticals Ltd.	Terapeutski pripravci koji sadrže macitentan

2009
- 2009-08-12 HR HRP20171917TT patent/HRP20171917T1/hr unknown
- 2009-08-12 PT PT97869127T patent/PT2315587T/pt unknown
- 2009-08-12 PL PL17191033T patent/PL3300729T3/pl unknown
- 2009-08-12 SI SI200932016T patent/SI3300729T1/sl unknown
- 2009-08-12 HU HUE17191033A patent/HUE047767T2/hu unknown
- 2009-08-12 KR KR1020117003547A patent/KR101678699B1/ko active Active
- 2009-08-12 AU AU2009280843A patent/AU2009280843B2/en active Active
- 2009-08-12 TW TW098127151A patent/TWI446911B/zh active
- 2009-08-12 BR BRPI0917661A patent/BRPI0917661B8/pt not_active IP Right Cessation
- 2009-08-12 NZ NZ591601A patent/NZ591601A/xx unknown
- 2009-08-12 LT LTEP17191033.4T patent/LT3300729T/lt unknown
- 2009-08-12 NO NO09786912A patent/NO2315587T3/no unknown
- 2009-08-12 ES ES09786912.7T patent/ES2652590T3/es active Active
- 2009-08-12 CA CA2731370A patent/CA2731370C/en active Active
- 2009-08-12 PL PL09786912T patent/PL2315587T3/pl unknown
- 2009-08-12 US US13/058,639 patent/US8809334B2/en active Active
- 2009-08-12 MY MYPI2011000637A patent/MY178894A/en unknown
- 2009-08-12 AR ARP090103113A patent/AR073031A1/es not_active Application Discontinuation
- 2009-08-12 DK DK17191033.4T patent/DK3300729T3/da active
- 2009-08-12 HU HUE09786912A patent/HUE036071T2/hu unknown
- 2009-08-12 CN CN2009801279936A patent/CN102099026B/zh not_active Expired - Fee Related
- 2009-08-12 SM SM20190740T patent/SMT201900740T1/it unknown
- 2009-08-12 ES ES17191033T patent/ES2763176T3/es active Active
- 2009-08-12 DK DK09786912.7T patent/DK2315587T3/en active
- 2009-08-12 MX MX2011001625A patent/MX350011B/es active IP Right Grant
- 2009-08-12 LT LTEP09786912.7T patent/LT2315587T/lt unknown
- 2009-08-12 WO PCT/IB2009/053553 patent/WO2010018549A2/en not_active Ceased
- 2009-08-12 PT PT171910334T patent/PT3300729T/pt unknown
- 2009-08-12 SI SI200931770T patent/SI2315587T1/en unknown
- 2009-08-12 EP EP09786912.7A patent/EP2315587B1/en not_active Revoked
- 2009-08-12 EP EP17191033.4A patent/EP3300729B1/en not_active Revoked
- 2009-08-12 JP JP2011522608A patent/JP5764061B2/ja not_active Expired - Fee Related
- 2009-08-12 SM SM20170592T patent/SMT201700592T1/it unknown
- 2009-08-12 RU RU2011109084/15A patent/RU2519161C2/ru active
2011
- 2011-02-10 IL IL211143A patent/IL211143A0/en active IP Right Grant
- 2011-03-07 MA MA33675A patent/MA32614B1/fr unknown
- 2011-03-11 ZA ZA2011/01900A patent/ZA201101900B/en unknown
2014
- 2014-07-18 US US14/335,657 patent/US9173881B2/en active Active
2015
- 2015-06-12 JP JP2015119020A patent/JP5956025B2/ja active Active
- 2015-06-12 JP JP2015119021A patent/JP5956026B2/ja active Active
- 2015-10-02 US US14/873,787 patent/US9597331B2/en active Active
2018
- 2018-01-19 CY CY20181100074T patent/CY1119826T1/el unknown
- 2018-10-03 HK HK18112650.6A patent/HK1253355B/en not_active IP Right Cessation
2019
- 2019-12-06 HR HRP20192204TT patent/HRP20192204T1/hr unknown
2020
- 2020-01-08 CY CY20201100016T patent/CY1122641T1/el unknown

Also Published As

Publication number	Publication date
PT2315587T (pt)	2018-01-31
SI3300729T1 (sl)	2020-02-28
HK1253355B (en)	2020-06-19
JP5956025B2 (ja)	2016-07-20
SMT201700592T1 (it)	2018-03-08
HK1253355A1 (en)	2019-06-14
CA2731370A1 (en)	2010-02-18
AR073031A1 (es)	2010-10-06
WO2010018549A2 (en)	2010-02-18
HRP20171917T1 (hr)	2018-02-09
PT3300729T (pt)	2020-01-20
TWI446911B (zh)	2014-08-01
HRP20192204T1 (hr)	2020-03-06
CN102099026B (zh)	2012-08-29
AU2009280843B2 (en)	2015-03-05
MY178894A (en)	2020-10-21
US9173881B2 (en)	2015-11-03
KR101678699B1 (ko)	2016-11-23
RU2519161C2 (ru)	2014-06-10
PL3300729T3 (pl)	2020-04-30
LT3300729T (lt)	2020-01-10
CY1122641T1 (el)	2021-03-12
JP2011530581A (ja)	2011-12-22
US8809334B2 (en)	2014-08-19
ZA201101900B (en)	2012-08-29
MA32614B1 (fr)	2011-09-01
DK2315587T3 (en)	2018-01-02
JP2015187148A (ja)	2015-10-29
EP3300729A1 (en)	2018-04-04
NZ591601A (en)	2012-12-21
ES2763176T3 (es)	2020-05-27
BRPI0917661B1 (pt)	2019-12-17
US20110136818A1 (en)	2011-06-09
SI2315587T1 (en)	2018-04-30
WO2010018549A3 (en)	2010-07-29
NO2315587T3 (pt)	2018-03-24
LT2315587T (lt)	2018-01-10
RU2011109084A (ru)	2012-09-20
AU2009280843A1 (en)	2010-02-18
HUE036071T2 (hu)	2018-06-28
US9597331B2 (en)	2017-03-21
BRPI0917661B8 (pt)	2021-05-25
EP3300729B1 (en)	2019-10-09
US20160022678A1 (en)	2016-01-28
CA2731370C (en)	2017-03-14
JP5764061B2 (ja)	2015-08-12
DK3300729T3 (da)	2020-01-20
HUE047767T2 (hu)	2020-05-28
JP5956026B2 (ja)	2016-07-20
US20140329824A1 (en)	2014-11-06
MX350011B (es)	2017-08-22
KR20110045006A (ko)	2011-05-03
IL211143A0 (en)	2011-04-28
CN102099026A (zh)	2011-06-15
ES2652590T3 (es)	2018-02-05
PL2315587T3 (pl)	2018-03-30
SMT201900740T1 (it)	2020-01-14
JP2015180683A (ja)	2015-10-15
EP2315587B1 (en)	2017-10-25
TW201010985A (en)	2010-03-16
EP2315587A2 (en)	2011-05-04
CY1119826T1 (el)	2018-06-27
MX2011001625A (es)	2011-03-29

Publication	Publication Date	Title
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0809667A2 (pt)	2014-10-07	Composto, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0921699A2 (pt)	2016-02-16	complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI0917315A2 (pt)	2015-11-17	anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
BRPI0914343A2 (pt)	2016-07-26	composição, produto, uso da composição e método
BRPI0821004A2 (pt)	2015-06-16	Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BR112012002331A2 (pt)	2019-09-24	composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0819299A2 (pt)	2014-10-07	Uso de composição, e, composição contendo proteína
BRPI0816350A2 (pt)	2015-02-24	Composições orais, produtos e métodos de uso
BRPI0815190A2 (pt)	2015-03-31	Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0908208A2 (pt)	2015-08-25	Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0809661A2 (pt)	2014-10-14	Composição farmacêutica estabilizada contendo pregabalina
BRPI1012201A2 (pt)	2016-04-05	composto anticacerígeno e composição farmacêutica que o contém
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI0907892A2 (pt)	2015-07-28	Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
EP2474522A4 (en)	2013-03-20	AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
BRPI0908859A2 (pt)	2017-06-06	composição farmacêutica estabilizada de líquído único contedo docetaxel
BRPI0821327A2 (pt)	2015-06-16	Derivado de catecol, composição farmacêutica contendo o mesmo, uso do derivado de catecol, e uso da composição farmacêutica

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-08-28	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-02-05	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-10-15	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-12-17	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/12/2019, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-06-04	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2024-09-24	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2787 DE 04-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.